Differences In Hematology And Bcr-Abl Molecular Profiles In Patients With Chronic Myeloid Leukemia Undergoing Tyrosine Kinase Inhibitor Therapy

Chronic myeloid leukemia (CML) is a myeloproliferative malignancy due to the formation of BCR-ABL fusion gene in chronic leukemia. This condition causes excessive cell proliferation, resulting an increase number leukocytes. Tyrosine Kinase Inhibitor (TKI) first-line therapy that helps reduce percentage patients with study was conducted determine differences hematological profiles (hemoglobin levels, leukocyte counts, platelet counts) and molecular before after 12 months tyrosine kinase inhibitors therapy. analytic observational administered using cross-sectional design analyzing medical records CML who underwent TKI at Sub Specialist Polyclinic Internal Medicine Hematology Oncology Ulin Banjarmasin Regional Hospital from March 2021-April 2022. Dependent T-test McNemar's test were performed data analysis which results showed month inhibitor could hemoglobin decrease counts as well decreasing In conclusion, significant found (p<0.001)